share_log

友芝友生物-B(02496.HK)：双特异性抗体M701恶性腹水III期临床试验完成首例患者入组

Tomoshibayu Bio-B (02496.HK): Phase III clinical trial of the bispecific antibody M701 malignant ascites completed the first patient enrollment

Gelonghui Finance ·  Mar 27 09:16

On March 27, Ge Longhui | Youzhiyou Bio-B (02496.HK) announced that M701, an investigational bispecific antibody (“BsAb”) that targets both epithelial cell adhesion molecule (“epCAM”) and differentiation cluster 3 (“CD3”) independently developed by the company, recently completed the first case of patients enrolled in a critical phase III registered clinical trial (“malignant ascites study”). The purpose of the malignant ascites study was to evaluate the efficacy and safety of peritoneal perfusion M701 compared with abdominal puncture drainage in patients with malignant ascites caused by advanced solid epithelial tumors. If successful, the malignant ascites study will be used to support M701's marketing license application for the first indication in China.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment